The Medulloblastoma drugs in development market research report provides comprehensive information on the therapeutics under development for Medulloblastoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Medulloblastoma. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Medulloblastoma and features dormant and discontinued products.

GlobalData tracks 69 drugs in development for Medulloblastoma by 64 companies/universities/institutes. The top development phase for Medulloblastoma is preclinical with 28 drugs in that stage. The Medulloblastoma pipeline has 56 drugs in development by companies and 13 by universities/ institutes. Some of the companies in the Medulloblastoma pipeline products market are: Bristol-Myers Squibb, MacroGenics and Oncoheroes Biosciences.

The key targets in the Medulloblastoma pipeline products market include Smoothened Homolog (Protein Gx or SMO), Signal Transducer And Activator Of Transcription 3 (Acute Phase Response Factor or DNA Binding Protein APRF or STAT3), and Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22).

The key mechanisms of action in the Medulloblastoma pipeline product include Smoothened Homolog (Protein Gx or SMO) Antagonist with four drugs in Phase I. The Medulloblastoma pipeline products include 18 routes of administration with the top ROA being Oral and nine key molecule types in the Medulloblastoma pipeline products market including Small Molecule, and Monoclonal Antibody.

Medulloblastoma overview

Medulloblastoma is the most common malignant brain tumor in children. Medulloblastoma by definition occurs in the cerebellum, which is the part of brain located at the base of the skull, just above the brainstem. Symptoms associated with a medulloblastoma include headaches in the morning that improve as the day goes on, recurrent vomiting, and difficulty with walking and balance. Medulloblastoma can spread to other areas of the central nervous system. Treatment includes options such as chemotherapy, surgery, biological therapy, and radiation therapy.

For a complete picture of Medulloblastoma’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.